STOCK TITAN

Purple Biotech (PPBT) director details shares, RSUs and option grants

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
3

Rhea-AI Filing Summary

PURPLE BIOTECH LTD. director Suzana Zilberberg filed an initial ownership report showing her equity stake in the company. She directly holds 3,062,500 Ordinary Shares as of the reported date, including 2,454,167 unvested restricted stock units that will settle in Ordinary Shares.

She also holds stock options to purchase 112,500 Ordinary Shares at $0.126875 per share expiring on December 29, 2026, options for 300,000 Ordinary Shares at $0.059375 per share expiring on April 24, 2028, and options for 2,650,000 Ordinary Shares at $0.00309375 per share expiring on October 21, 2030, with portions of these options vesting over time.

Positive

  • None.

Negative

  • None.
Insider Zilberberg Suzana
Role Director
Type Security Shares Price Value
holding Stock Option (Right to Buy) -- -- --
holding Stock Option (Right to Buy) -- -- --
holding Stock Option (Right to Buy) -- -- --
holding Ordinary Shares -- -- --
Holdings After Transaction: Stock Option (Right to Buy) — 112,500 shares (Direct); Ordinary Shares — 3,062,500 shares (Direct)
Footnotes (1)
  1. Includes 2,454,167 unvested restricted stock units ("RSUs"), each with respect to one ordinary share, no par value, per share ("Ordinary Shares"), of Purple Biotech Ltd. (the "Issuer"). The RSUs are subject to time-based vesting conditions and are settled in Ordinary Shares. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents 2,000 Ordinary Shares Represents stock option to purchase 112,500 Ordinary Shares (equivalent to 150 ADSs), issued to the reporting person pursuant to the Issuer's 2016 Equity-Based Incentive Plan. The stock option is fully vested and exercisable. The exercise price of this stock option is $0.126875 per Ordinary Share and the option expires on December 29, 2026. Represents stock option to purchase 300,000 Ordinary Shares (equivalent to 150 ADSs), issued to the reporting person pursuant to the Issuer's 2016 Equity-Based Incentive Plan. Options to purchase 274,997 Ordinary Shares are vested and exercisable, with the remaining options to purchase 25,003 Ordinary Shares vesting in equal quarterly installments until April 24, 2026. The exercise price of this stock option is $0.059375 per Ordinary Share and the option expires on April 24, 2028. Represents stock option to purchase 2,650,000 Ordinary Shares (equivalent to 1,325 ADSs), issued to the reporting person pursuant to the Issuer's 2016 Equity-Based Incentive Plan. Options to purchase 220,833 Ordinary Shares are vested and exercisable, with the remaining options to purchase 2,429,167 Ordinary Shares vesting in equal quarterly installments until October 21, 2028. The exercise price of this stock option is $0.00309375 per Ordinary Share and the option expires on October 21, 2030.
Ordinary Shares held 3,062,500 Ordinary Shares Direct holdings as of transaction date
Unvested RSUs 2,454,167 RSUs Each RSU for one Ordinary Share, time-based vesting
Option grant 1 size 112,500 Ordinary Shares Fully vested stock option, expires December 29, 2026
Option grant 1 exercise price $0.126875 per Ordinary Share Exercise price for 112,500-share option
Option grant 2 size 300,000 Ordinary Shares Partially vested, fully vests by April 24, 2026
Option grant 2 exercise price $0.059375 per Ordinary Share Exercise price for 300,000-share option
Option grant 3 size 2,650,000 Ordinary Shares Partially vested, fully vests by October 21, 2028
Option grant 3 exercise price $0.00309375 per Ordinary Share Exercise price for 2,650,000-share option
restricted stock units financial
"Includes 2,454,167 unvested restricted stock units ("RSUs"), each with respect to one ordinary share"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
American Depositary Shares financial
"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents 2,000 Ordinary Shares"
American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.
exercise price financial
"The exercise price of this stock option is $0.126875 per Ordinary Share and the option expires"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
time-based vesting conditions financial
"The RSUs are subject to time-based vesting conditions and are settled in Ordinary Shares."
Equity-Based Incentive Plan financial
"issued to the reporting person pursuant to the Issuer's 2016 Equity-Based Incentive Plan."
SEC Form 3
FORM 3UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0104
Estimated average burden
hours per response:0.5
1. Name and Address of Reporting Person*
Zilberberg Suzana

(Last)(First)(Middle)
4 OPPENHEIMER STREET

(Street)
SCIENCE PARK, REHOVOT7670104

(City)(State)(Zip)

ISRAEL

(Country)
2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026
3. Issuer Name and Ticker or Trading Symbol
PURPLE BIOTECH LTD. [ PPBT ]
3a. Foreign Trading Symbol
5. If Amendment, Date of Original Filed (Month/Day/Year)
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares3,062,500(1)D
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year)3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy) (2) (2)Ordinary Shares112,500(2)D
Stock Option (Right to Buy) (3) (3)Ordinary Shares300,000(3)D
Stock Option (Right to Buy) (4) (4)Ordinary Shares2,650,000(4)D
Explanation of Responses:
1. Includes 2,454,167 unvested restricted stock units ("RSUs"), each with respect to one ordinary share, no par value, per share ("Ordinary Shares"), of Purple Biotech Ltd. (the "Issuer"). The RSUs are subject to time-based vesting conditions and are settled in Ordinary Shares. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents 2,000 Ordinary Shares
2. Represents stock option to purchase 112,500 Ordinary Shares (equivalent to 150 ADSs), issued to the reporting person pursuant to the Issuer's 2016 Equity-Based Incentive Plan. The stock option is fully vested and exercisable. The exercise price of this stock option is $0.126875 per Ordinary Share and the option expires on December 29, 2026.
3. Represents stock option to purchase 300,000 Ordinary Shares (equivalent to 150 ADSs), issued to the reporting person pursuant to the Issuer's 2016 Equity-Based Incentive Plan. Options to purchase 274,997 Ordinary Shares are vested and exercisable, with the remaining options to purchase 25,003 Ordinary Shares vesting in equal quarterly installments until April 24, 2026. The exercise price of this stock option is $0.059375 per Ordinary Share and the option expires on April 24, 2028.
4. Represents stock option to purchase 2,650,000 Ordinary Shares (equivalent to 1,325 ADSs), issued to the reporting person pursuant to the Issuer's 2016 Equity-Based Incentive Plan. Options to purchase 220,833 Ordinary Shares are vested and exercisable, with the remaining options to purchase 2,429,167 Ordinary Shares vesting in equal quarterly installments until October 21, 2028. The exercise price of this stock option is $0.00309375 per Ordinary Share and the option expires on October 21, 2030.
/s/ Suzana Nahum-Zilberberg04/07/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does the Purple Biotech (PPBT) Form 3 filing by Suzana Zilberberg show?

The Form 3 filing shows director Suzana Zilberberg’s initial ownership in Purple Biotech. She reports direct holdings of Ordinary Shares, a large block of unvested RSUs, and several stock option grants with specified exercise prices and expiration dates.

How many ordinary shares does Suzana Zilberberg hold in Purple Biotech (PPBT)?

Suzana Zilberberg reports 3,062,500 Ordinary Shares held directly as of the reported date. This figure includes 2,454,167 unvested restricted stock units that will settle in Ordinary Shares as vesting conditions are satisfied over time.

What restricted stock units (RSUs) are disclosed for Suzana Zilberberg in PPBT?

She holds 2,454,167 unvested RSUs, each representing one Ordinary Share of Purple Biotech. These RSUs are subject to time-based vesting and are settled in Ordinary Shares, which may be represented by American Depositary Shares according to the disclosure.

What stock option grants does Suzana Zilberberg have in Purple Biotech (PPBT)?

She holds three stock option grants: 112,500 shares at $0.126875, 300,000 shares at $0.059375, and 2,650,000 shares at $0.00309375 per Ordinary Share, each with different vesting schedules and expiration dates extending to October 21, 2030.

Are Suzana Zilberberg’s stock options in PPBT fully vested?

One grant for 112,500 Ordinary Shares is fully vested. For the 300,000-share grant, 274,997 are vested, with 25,003 vesting quarterly until April 24, 2026. For the 2,650,000-share grant, 220,833 are vested, with the rest vesting quarterly until October 21, 2028.

How are American Depositary Shares (ADSs) referenced in the Purple Biotech (PPBT) Form 3?

The filing notes that Ordinary Shares may be represented by ADSs, with each ADS currently representing 2,000 Ordinary Shares. This gives investors context on how the Israeli company’s Ordinary Shares translate into ADSs traded in international markets.